Nelotanserin

Drug Profile

Nelotanserin

Alternative Names: APD-125

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Axovant Sciences
  • Class Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lewy body disease
  • Discontinued Insomnia

Most Recent Events

  • 13 Feb 2017 Interim efficacy and adverse events data from a phase II trial in Lewy body dementia released by Axovant Biosciences
  • 13 Feb 2017 Axovant Biosciences plans a phase III registration trial for Lewy body dementia
  • 01 Aug 2016 Axovant Sciences initiates a phase-II clinical trial in Lewy body disease (In adults, In the elderly) in USA (NCT02871427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top